



"I've been fighting Crohn's disease with a biologic medication for as long as I can remember. When I turned 26, I switched health care plans, and the biologic that I had been taking for years wasn't covered anymore, but my doctor knew of a biosimilar that would be. So we made the change, and now I don't pay anything for my infusions."

- Eileen, 28, New York City

## CROHN'S & COLITIS PATIENTS SAVE WITH GENERIC DRUGS

### \$4.6 Billion Per Year

Generics saved patients with Crohn's and colitis \$4.6 billion in 2020, and savings for the past 10 years total \$23.6 billion.

According to the Crohn's & Colitis Foundation, inflammatory bowel diseases (IBD), which include Crohn's disease and ulcerative colitis, affect as many as 1.6 million Americans. Generic drugs can reduce the inflammation, allowing patients to lead more active, fulfilling lives.

### Generics and Biosimilar Medicines Deliver More Savings Every Year

Because tens of millions of Americans entrust their health to generics and biosimilars, they saved \$338 billion in 2020, and nearly \$2.4 trillion in the last decade.

### Conditions That Often Accompany Crohn's & Colitis

Many Crohn's & colitis patients also take generic medications for other conditions:

15% have anemia,  
for which they saved

**\$475M**

6.2% have colorectal cancer,  
for which they saved

**\$3.2B**

#### TOP 10 GENERIC SAVINGS BY CONDITION IN 2020

| CONDITION                             | GENERIC SAVINGS  |
|---------------------------------------|------------------|
| HEART DISEASE                         | \$88,062,760,793 |
| MENTAL HEALTH                         | \$56,069,886,013 |
| DIABETES                              | \$53,214,066,373 |
| EPILEPSY                              | \$36,692,231,940 |
| CANCERS                               | \$15,972,778,545 |
| ALLERGIES & ASTHMA                    | \$13,640,813,324 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | \$5,674,341,924  |
| ALZHEIMER'S DISEASE                   | \$5,279,870,992  |
| HIV/AIDS                              | \$4,786,180,477  |
| CROHN'S & COLITIS                     | \$4,591,855,045  |

Source: IQVIA, National Sales Perspectives, Dec 2020.

**31**  
Approvals

Projected Savings  
Through 2025  
**\$133 Billion**

**20**  
Launched

Biosimilars have been used in more than **121 million days** of patient therapy and have resulted in almost **10 million incremental days** of therapy.

As of October 2021.  
Source: U.S. FDA.